Use of an Online Community to Develop Patient-Reported Outcome Instruments: The Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)
暂无分享,去创建一个
Paul Wicks | Michael Massagli | M. Massagli | P. Wicks | H. Dastani | Amit Kulkarni | Amit Kulkarni | Homa Dastani
[1] D. Cox,et al. A Prospective Baseline Versus On‐Treatment Study Assessing Patient Perceptions of Using a Smaller Needle When Injecting Intramuscular Interferon Beta‐1a (Avonex) , 2008, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[2] Gunther Eysenbach,et al. Improving the Quality of Web Surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES) , 2004, Journal of medical Internet research.
[3] James R. Miller. The importance of early diagnosis of multiple sclerosis. , 2004, Journal of managed care pharmacy : JMCP.
[4] D. Mohr,et al. Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. , 2002, Journal of behavior therapy and experimental psychiatry.
[5] Jared M. Bruce,et al. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report , 2010, Multiple sclerosis.
[6] A. al‐Sabbagh,et al. Patient satisfaction with an injection device for multiple sclerosis treatment , 2006, Acta neurologica Scandinavica.
[7] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[8] G. Willis,et al. Cognitive Interviewing: A Tool for Improving Questionnaire Design , 2004 .
[9] S. De Geest,et al. Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.
[10] P. Fontoura,et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis , 2011, European journal of neurology.
[11] J. Frost,et al. Sharing Health Data for Better Outcomes on PatientsLikeMe , 2010, Journal of medical Internet research.
[12] D. Hoaglin,et al. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics , 2006, Multiple sclerosis.
[13] D. Cox,et al. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. , 2006, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[14] D. Wingerchuk,et al. Current Evidence and Therapeutic Strategies for Multiple Sclerosis , 2008, Seminars in neurology.
[15] X. Montalban,et al. Interferon beta in secondary progressive multiple sclerosis , 2007, Journal of Neurology.
[16] Yelena Rozenfeld,et al. Oral antidiabetic medication adherence and glycemic control in managed care. , 2008, The American journal of managed care.
[17] P. Laurent,et al. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis , 2008, BMC neurology.
[18] R. Marrie,et al. Validation of the NARCOMS registry: diagnosis , 2007, Multiple sclerosis.
[19] J. Haselkorn,et al. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model , 2007, Multiple sclerosis.
[20] P. Vermersch,et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[21] Arthur L. Allen,et al. Factors that influence adherence with disease-modifying therapy in MS , 2009, Journal of Neurology.
[22] Kathleen Costello,et al. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. , 2008, Medscape journal of medicine.
[23] X. Montalban,et al. Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis , 2005, Multiple sclerosis.
[24] C. McHorney,et al. Frequency of and reasons for medication non‐fulfillment and non‐persistence among American adults with chronic disease in 2008 , 2011, Health expectations : an international journal of public participation in health care and health policy.
[25] Paul Wicks,et al. The power of social networking in medicine , 2009, Nature Biotechnology.
[26] D. Goodkin,et al. Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and infection anxiety on adherence and ability to self-inject , 2001, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.
[27] M. Dimatteo. Variations in Patients’ Adherence to Medical Recommendations: A Quantitative Review of 50 Years of Research , 2004, Medical care.
[28] Ludwig Kappos,et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[29] F. Reed Johnson,et al. Multiple sclerosis patients—benefit-risk preferences: Serious adverse event risks versus treatment efficacy , 2009, Journal of Neurology.
[30] R. Marrie,et al. Validation of the NARCOMS Registry: fatigue assessment , 2005, Multiple sclerosis.
[31] H. Tremlett,et al. Interrupted therapy , 2003, Neurology.
[32] Ludwig Kappos,et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[33] M Hutchinson,et al. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns , 2005, Multiple sclerosis.
[34] T. Berger. ‘Let’s stick together’ Adherence to disease‐modifying therapies in multiple sclerosis , 2011, European journal of neurology.
[35] D. Mohr,et al. Self-Injection Anxiety Training: a treatment for patients unable to self-inject injectable medications , 2005, Multiple sclerosis.
[36] T. Dwyer,et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses , 2008, Pharmacoepidemiology and drug safety.
[37] Jeffrey A Cohen,et al. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. , 2006, Cleveland Clinic journal of medicine.
[38] Sally Okun,et al. Patient-reported Outcomes as a Source of Evidence in Off-Label Prescribing: Analysis of Data From PatientsLikeMe , 2011, Journal of medical Internet research.
[39] Jared M. Bruce,et al. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition , 2010, Journal of Behavioral Medicine.